Switzerland's Mymetics says that its experimental malaria vaccine could be ready for marketing as early as 2014. CEO Christain Rochet says that clinical trials on the vaccine--obtained from Pevion--have been carried out in Britain and Switzerland as well as developing nations. It should take another three years to complete clinical work on the vaccine, says Rochet, leading the company to conclude that marketing approval could come in six years.
"There is a pressing need for a vaccine against malaria," said the CEO. "Up to 500 million people a year are infected, with a mortality rate of approximately two million each year."
- read the AFP report